Kornimate/medical-research-clean huggingface dataset:
acute effect of whole body vibration on reaction speed and proprioception

Conditions: Whole Body Vibration

Summary: it will be determined whether the application of whole body vibration has an immediate effect on upper extremity reaction speed and proprioception.

muscles and tendons are among the mechanisms affected by whole body vibration. in this way, it is thought that tvv indirectly affects the reaction speed of individuals. in the light of this information, this study was planned to investigate how whole body vibration application affects proprioception and reaction speed. the reaction rate and instantaneous effect of the virion given at 30 hz and 2 mm amplitude in the push-up position on proprioception will be investigated. the aim of this study is to investigate the instantaneous effect of whole body vibration on reaction speed and proprioception in the upper extremity in healthy individuals.

Eligibility criteria:
inclusion criteria: * healthy individuals between the ages of 18-25 * those who do not have any orthopedic problems in the upper extremity * individuals without any neurological problems * those who volunteer to participate in the study exclusion criteria: * those who have vertigo

Keywords: whole body vibration healthy subject reaction time proprioception upper extremity
metabolic imaging of neurological disease

Conditions: Multiple Sclerosis

Summary: multiple sclerosis is a chronic condition that shows changes in the way that the brain consumes sugar. it is also known that there are a number of metabolic and inflammatory sequelae following a transient ischemic attack/stroke (hereby referred to collectively as 'stroke'). this study will use a powerful new technology ('hyperpolarised magnetic resonance imaging') to detect these changes in the brains of people with multiple sclerosis and clinically isolated syndrome (cis) or following a stroke when compared to a group of healthy volunteers. it will be undertaken at the university of oxford, and each participant will undergo up to 4 scans over the course of three years.


Eligibility criteria:
inclusion criteria: * diagnosis of ms or stroke exclusion criteria: -
phenylephrine tumescence for hemostasis in surgery for burn injury

Conditions: Blood Loss, Surgical

Summary: the standard of care for treatment of burn injury is to inject a solution of epinephrine under the skin of the injured site in order to reduce blood loss during skin grafting. this solution of epinephrine has been shown to have effects on the body outside the donor site. some people have increases in heart rate and blood pressure. we will study the effect of a phenylephrine solution in place of an epinephrine solution to control blood loss. we think that phenylephrine will help decrease blood loss and not change blood pressure or heart rate. the injured area will be injected under the skin and a skin graft will be taken in the same way as we usually do. the only change will be the use of phenylephrine in the solution instead of epinephrine. our goal is to find whether or not phenylephrine or epinephrine solution results in a reduction of blood loss without affecting the rest of the body.


Eligibility criteria:
inclusion criteria a) burn injury requiring debridement and grafting between 5-30% tbsa exclusion criteria 1. head and neck, hand, foot, or genital burns 2. on anticoagulants (except nsaids) 3. on monoamine oxidase inhibitor or tricyclic antidepressant 4. coronary or peripheral vascular disease 5. history of arrhythmias 6. on a beta-blocker 7. history of vascular abnormality 8. hypertension

Keywords: blood loss burn hemostasis
study of tumor samples from patients with ependymoma treated on the children's oncology group acns0121 trial

Conditions: Childhood Infratentorial Ependymoma; Childhood Supratentorial Ependymoma; Newly Diagnosed Childhood Ependymoma

Summary: this research trial studies tumor samples from patients with ependymoma treated on the children oncology group acns0121 trial. studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. it may also help doctors find better ways to treat cancer.

primary objectives: i. to examine the prognostic role of histopathological variables, in particular cellular density, mitotic count, and tumor cell invasion in intracranial pediatric ependymomas. ii. to study whether htert expression and telomere dysfunction correlate with progression-free survival (pfs) and overall survival (os) in pediatric intracranial ependymoma. iii. to perform a genome-wide copy number screen and validation of copy number abnormalities (cnas) on formalin-fixed paraffin-embedded (ffpe) ependymomas using affymetrix molecular inversion probe (mip) arrays and interphase fluorescence in situ hybridization (ifish). iv. to evaluate associations between infiltration of immune markers and pfs as well as os in pediatric ependymoma. v. to examine the role of 1q gain and 9p deletion in pediatric ependymomas by exploring their association with pfs and os in a multivariable model. vi. to establish the frequency and clinicopathological associations of mutations in genes involved in notch pathway signaling. outline: archived tumor tissue samples are analyzed for cellular density, mitotic count, tumor cell invasion, htert expression, telomere dysfunction, 1q gain, 9p deletion, and genetic mutations by ihc, affymetrix molecular inversion probe (mip) arrays, and fluorescence in situ hybridization (fish). results are then correlated with patient-outcome variables and known risk factors, namely gender, age at diagnosis, tumor location infratentorial vs. supratentorial), tumor grade (differentiated vs anaplastic), and extent of surgery as well as pathologic variables.

Eligibility criteria:
inclusion criteria: * diagnosed with ependymoma and treated on cog-acns0121 * previously collected tumor samples banked at the children oncology group biopathology
effects of health care provider-mediated, remote coaching system through the pda-type glucometer and the internet on diabetes management

Conditions: Type 2 Diabetes; Lifestyle Intervention; Glucose Control; Internet Communication

Summary: the purpose of this study is to investigate the effectiveness of the new diabetes care delivery system applied to preexisting public health care resources through advanced information technologies such as pda-type glucometer and the internet on the glycemic control of type 2 diabetes patients lived in isolated rural area. the investigators conducted a prospective, randomized, controlled trial in patients with type 2 diabetes for 12 weeks. the intervention group was treated with the new health care delivery system, where diabetes center provided specialized management, mediated by nurse of primary health care posts using the internet and the pda-type glucometer, while the control group with conventional health care. hba1c, fasting plasma glucose and lipids levels were measured at baseline and follow-up.


Eligibility criteria:
inclusion criteria: * type 2 diabetes patients * aged ≥ 40 years * baseline hba1c of 7.0 to 11.0 % who had been already followed up for more than 6 months in the health care post exclusion criteria: * participants with diagnosed or suspected disease of the liver, pancreas, endocrine organs, or kidney * ischemic heart disease or cerebrovascular disease or a history of such disease * a creatinine level \> 0.133 mmol/l * treatment with an intensified insulin regimens and those unable .

Keywords: diabetes pda internet hba1c
correlation between macular ischemia and peripheral ischemia in patients with diabetes

Conditions: Diabetic Retinopathy

Summary: the contribution of oct- angiography (oct-a) allows to consider, in a more or less long term, a drastic reduction in the use of fluorescein angiographies in diabetic retinopathy. the accuracy of the analysis of the vascularization of retinal layers of the posterior pole of the eye by the oct-a , will detect, early and in a quantifiable manner, whether or not there are areas of macular ischemia in a patient. however, current technical limitations (small field analysis) of oct-a imaging only allow a limited study of retina at the posterior pole of the fundus. this study seeks to demonstrate whether there is a link between macular ischemia detected by the oct-a and peripheral retinal ischemia detected by the fluorescein angiographies, in diabetic patients.


Eligibility criteria:
inclusion criteria: * diabetes type i or type ii * follow-up with fluorescein angiography exclusion criteria: * known allergy to fluorescein * contra-indication to fluorescein angiography * pregnant or breast-feeding patient * technical impossibility to analyse retinal ischemic areas on fluorescein angiography or oct-a.
oral health of individuals who attended a mother-child dental care program - longitudinal study

Conditions: Health Behavior

Summary: the aim of this longitudinal study was to assess the oral health of individuals attending a mother-child dental care program (pppwb). the mean dmft and gbi in the second phase and the control group were 0.75 and 6.75, 1.47 and 10.74, respectively. it was concluded that the individuals who attended the pppwb had better oral health status than the control group. when the two phases of the study were compared, it was noted that the individuals in the second phase had better oral health, although they had a higher score for gingival bleeding.

the aim of this longitudinal study was to assess the oral health of individuals attending a mother-child dental care program (pppwb). letters were sent to the 343 children who were examined in phase 1. one hundred and thirty nine individuals returned for the oral examination - experimental group (40.5%). the control group consisted of 139 individuals who did not receive dental care from the pppwb. these individuals were paired to the experimental group according to their age and socio-demographic characteristics. gingival bleeding (gbi) and dmft indices were used in order to determine the children's oral health status. the mean dmft and gbi in the second phase and the control group were 0.75 and 6.75, 1.47 and 10.74, respectively. it was concluded that the individuals who attended the pppwb had better oral health status than the control group. when the two phases of the study were compared, it was noted that the individuals in the second phase had better oral health, although they had a higher score for gingival bleeding.

Eligibility criteria:
inclusion criteria: * children who participated to the program exclusion criteria: * children who did not participate

Keywords: dental caries epidemiology gingivitis oral health
study of decitabine for treatment of older patients with acute myeloid leukemia (aml)

Conditions: Acute Myeloid Leukemia

Summary: the purpose of this study is to estimate the rate of complete remission, as well as overall survival, in older patients with acute myeloid leukemia (aml).


Eligibility criteria:
inclusion criteria: 1. a diagnosis of aml or transformed from myelodysplastic syndrome (mds) within 2 weeks of study enrollment. 2. ineligible to receive intensive chemotherapy for their disease. 3. have not received any chemotherapy within 4 weeks of study enrollment and must have recovered from any treatment-related toxicities. exclusion criteria: 1. received previous treatment for aml. 2. previously received vidaza. 3. received any other investigational agents within 30 days of first dose of study drug. 4. uncontrolled intercurrent illness. 5. had radiotherapy within 14 days prior to study enrollment.

Keywords: acute myeloid leukemia aml decitabine dacogen mgi pharma, inc.
asthma comparative effectiveness study

Conditions: Asthma

Summary: the objective of this study is to compare the real-world effectiveness of bfc and fsc in asthma patients new to ics/laba combination therapy in a population of u.s. health plan enrollees.

a u.s. retrospective database analysis evaluating the comparative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol among asthma patients

Eligibility criteria:
inclusion criteria: * continuous health plan enrollment for 12 months before and after index rx * at least two prescription fills for bfc or fsc within 12 months * asthma claims diagnosis, and 12 to 64 years of age at the time of first prescription exclusion criteria: * evidence of copd * claims diagnosis of any of inflammatory diseases or cancer * presence of rx for more than one type of ics/laba combination on index date * chronic steroid use or xolair use prior to ics/laba index treatment

Keywords: asthma comparative effectiveness symbicort
short-term cervical spinal cord stimulation in patients with disorders of consciousness after intracerebral hemorrhage

Conditions: Coma; Stroke

Summary: disorders of consciousness (doc) refers to the persistent loss of consciousness after 28 days in patients with brain injury caused by trauma, stroke, or hypoxia. it includes coma, vegetative state, and minimally conscious state. at present, there is no effective treatment for doc. only one rct study of amantadine has proved that it may be effective for the treatment of doc. in recent years, more evidence has shown that neuromodulation technology is beneficial to the recovery of doc. cervical spinal cord stimulation surgery is a new treatment method for patients with doc. electrodes are implanted in the high cervical spinal cord c2-c5. by adjusting different electrical stimulation parameters, it has a wake-promoting effect. in this study, patients were selected into the spinal cord stimulation group and the conventional treatment group according to the wishes of their families. the patients in the spinal cord stimulation group were given 21 days of cervical spinal cord stimulation treatment on the basis of conventional brain rehabilitation. patients were followed up routinely and completed designated examinations at 12 months to determine the safety and efficacy of cervical spinal cord stimulation therapy.


Eligibility criteria:
inclusion criteria: * age between 18 and 65 years old * patients with postoperative consciousness disorders after cerebral hemorrhage for more than 28 days * crs-r score meets the mcs diagnosis * signed informed consent. exclusion criteria: * secondary brain injury caused by arteriovenous malformation, cerebral aneurysm, cavernous hemangioma, brain tumor and carbon monoxide poisoning * history of previous epileptic seizures * critical condition, unstable intracranial condition, risk of rebleeding * unstable vital signs requiring mechanical ventilation * contraindications for spinal cord surgery * severe sympathetic overactivity syndrome.
actual: efficacy and safety of irbesartan/hydrochlorothiazide combination

Conditions: Hypertension

Summary: to compare the antihypertensive efficacy of the combination irbesartan/hydrochlorothiazide (hctz) using either a usual or an active elective titration regimen. the main efficacy criteria will be the change in mean systolic blood pressure (sbp), measured at doctor's office with an automatic device, after a 10-week treatment period in hypertensive patients insufficiently controlled by monotherapy.


Eligibility criteria:
inclusion criteria: * established essential hypertension treated for at least 4 weeks by one antihypertensive drug alone * with uncontrolled blood pressure (bp) defined as: * sbp ≥ 160 mmhg and/or dbp ≥ 100 mmhg in non diabetic patients * sbp ≥ 150 mmhg and/or dbp ≥ 90 mmhg in diabetic patients exclusion criteria: * sbp ≥ 180 mmhg and/or dbp ≥ 110 mmhg at v1 * known or suspected causes of secondary hypertension * patient with bilateral renal artery stenosis, renal artery stenosis in a solitary kidney; history of renal transplant or only has one functioning kidney * associated cardiovascular conditions that prevent the patient from stopping the current antihypertensive drug (e.g.: beta-blocker for angina, ace-inhibitors for heart failure, etc...). * known hypersensitivity to diuretics or sulphonamides or history of angioedema or cough related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used * known contraindications to the study drugs: * severe renal dysfunction (creatinine clearance \<30ml/min) * known hypokaliemia (\< 3 mmol/l) , known hypercalcemia * severe hepatic impairment, biliary cirrhosis, cholestasis * inability to obtain a valid automatic bp measurement recording * administration of any other investigational drug within 30 days prior to study entry and during the course of the study * presence of any severe medical or psychological condition that, in the opinion of the investigator, indicate that participation in the study is not in the best interest of the subject. * presence of any other conditions (e.g. geographic, social, etc) that would restrict or limit the subject participation for the duration of the study. * pregnant or breast-feeding women * women of childbearing potential not protected by effective contraceptive method of birth control the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
rifaximin improves gut dysbiosis in insulin resistance and type 2 diabetes

Conditions: Type2 Diabetes

Summary: gut dysbiosis had been involved in some way in the pathogenesis of some extra-intestinal disorders including metabolic syndrome, cardiovascular disease, and obesity.

accumulating evidence had linked metabolic syndrome and diabetes to dysequilibrium in gut microbiota, which are a critical regulator of host metabolism and immune responses. gut microbiota interacts with host signaling pathways, leading to modulation of the endocrine system, immune responses. gut microbial metabolites, in particular, short-chain fatty acids, have been significantly associated with liability to diabetes. patients with positive fecal short-chain fatty acids will be given rifaximin

Eligibility criteria:
inclusion criteria: * diabetes with gut dysbiosis exclusion criteria: * recent antibiotic use * pregnancy * diabetogenic drugs

Keywords: gut dysbiosis rifaximin insulin resistance
health-related quality of life outcomes in patients with aggressive b-cell lymphomas treated with car-t cell therapy in real life

Conditions: DLBCL - Diffuse Large B Cell Lymphoma

Summary: this study will ultimately aim at providing the scientific community with patient-reported health status data that will contribute facilitate decision-makings. short- and long-term hrqol and symptoms will be evaluated in a longitudinal fashion over time to improve the understanding of the impact of the disease and car-t cell therapy on patients-wellbeing, symptom burden and daily functioning. this study will capture useful information on the impact of treatment toxicity, the burden of procedures on hrqol outcomes. the planned collection of pro and physician-reported adverse events ad early time point will help to compare and integrate these two points of view in healthcare assessment.

quality of life assessment

Eligibility criteria:
inclusion criteria: * patients with diffuse large b-cell lymphoma (dlbcl) not otherwise specified, primary mediastinal large b-cell lymphoma, high grade b-cell lymphoma, and dlbcl transformed by indolent lymphoma and mantle cell lymphoma. * scheduled to received car-t cell product. * having a baseline pro assessment. * adult patients (≥ 18 years old). * written informed consent provided. exclusion criteria: * having any documented or psychiatric or neurological disorder which may interfere with self-reported hrqol assessment. * not able to read and understand local language.
draw-10: a weekly blood draw study to understand the biological variability of plasma ptau-217

Conditions: Alzheimer Disease

Summary: this is an observational study that will serially collect 10 plasma samples over the course of 9 weeks from the same individuals to assess fluctuations in blood biomarker results.

blood biomarkers offer a less invasive and cheaper method for identifying alzheimer's disease (ad)-related changes. already, blood biomarkers for ad are being adopted by clinical practice and their use will only expand in coming years. however, blood biomarkers are susceptible to fluctuations not yet well characterized. such fluctuations, although rarely observed in current research settings, may influence the biological evaluation of dementia once implemented into routine settings. the study at present aims to identify how blood biomarkers fluctuate over a short period of time in the same individual and assess drivers of these fluctuations.

Eligibility criteria:
inclusion criteria: * able and wiling to provide informed consent * aged 50-80 years old at the time of signing study consent; participants aged 50-59 years will be no more than 20% of the total study population * has normal cognition or mild impairment at screening moca by a score of greater than or equal to 18; participants with a montreal cognitive assessment (moca test) score between 18-25 will be no more than 20% of the total study population * able and wiling to fully comply with study procedures defined in the protocol * written and spoken fluency in english exclusion criteria: * plans to begin any new treatment or is having surgery during the 9-week draw timeframe * currently enrolled in a clinical trial using an investigational drug

Keywords: plasma ptau217